US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Core High Dividend ETF

137.07

+1.361.00%

Post-market: 137.490.4200+0.31%19:33 EST

Volume:845.16K

Turnover:115.66M

Market Cap:13.28B

PE:- -

High:137.20

Open:136.03

Low:136.03

Close:135.71

52wk High:137.20

52wk Low:106.01

Shares:96.85M

Float Shares:96.85M

Volume Ratio:0.91

T/O Rate:0.87%

Dividend:3.91

Dividend Rate:2.85%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Libevitug Approved in China as First-in-Class Hepatitis D Treatment

Vir Biotechnology: Strengthening Best-in-Class HDV Profile with Robust SOLSTICE Data, Strategic Partnerships, and Sufficient Cash Runway Supporting Buy Rating

Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®

Vir Biotechnology’s Strategic Advancements in HDV and Oncology Programs Justify Buy Rating

RiboBio's HK IPO Journey: Balanced Pipeline and "China's Alnylam" Potential

Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection

Assembly Biosciences Announces Upcoming Investor Conference Participation

Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe

Vir Biotechnology: Strategic Dual-Franchise Growth and Promising Oncology and HDV Developments Support Buy Rating

Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting

Assembly Biosciences Announces Pricing of $175 Million in Equity Financings

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes

Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/HDV/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HDV","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HDV\",,,,,undefined,":{"symbol":"HDV","market":"US","secType":"STK","nameCN":"iShares Core High Dividend ETF","latestPrice":137.07,"timestamp":1770411600000,"preClose":135.71,"halted":0,"volume":845157,"hourTrading":{"tag":"盘后","latestPrice":137.49,"preClose":137.07,"latestTime":"19:33 EST","volume":7322,"amount":1003714.2149,"timestamp":1770424431701,"change":0.42,"changeRate":0.003064,"amplitude":0.004249},"delay":0,"changeRate":0.010021369095866076,"floatShares":96850000,"shares":96850000,"eps":0,"marketStatus":"Market Closed","change":1.36,"latestTime":"02-06 16:00:00 EST","open":136.03,"high":137.2,"low":136.03,"amount":115658839.58358,"amplitude":0.008621,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":135.71,"sharesOutstanding":97050000,"nav":135.72514,"aum":13172124837,"dividendRate":0.028518,"bidAskSpread":0.000201,"preHourTrading":{"tag":"盘前","latestPrice":136.1667,"preClose":135.71,"latestTime":"09:25 EST","volume":142,"amount":19298.85222,"timestamp":1770387937711,"change":0.4567,"changeRate":0.003365,"amplitude":0.013116},"postHourTrading":{"tag":"盘后","latestPrice":137.49,"preClose":137.07,"latestTime":"19:33 EST","volume":7322,"amount":1003714.2149,"timestamp":1770424431701,"change":0.42,"changeRate":0.003064,"amplitude":0.004249},"volumeRatio":0.906714,"impliedVol":0.1182,"impliedVolPercentile":0.6175},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HDV\",,,,,undefined,":{"symbol":"HDV","floatShares":96850000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.906714,"shares":96850000,"dividePrice":3.909,"high":137.2,"amplitude":0.008621,"preClose":135.71,"low":136.03,"week52Low":106.005,"pbRate":"--","week52High":137.2,"institutionHeld":0,"latestPrice":137.07,"eps":0,"divideRate":0.028518,"volume":845157,"delay":0,"ttmEps":0,"open":136.03,"prevYearClose":121.61,"prevWeekClose":132.19,"prevMonthClose":132.19,"prevQuarterClose":121.61},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HDV\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"HDV","amount":1.25288,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares High Dividend Equity Fun","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-09-16","symbol":"HDV","amount":0.949579,"announcedDate":"2025-09-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-16","defaultRemindTime":1758029400000,"name":"iShares High Dividend Equity Fun","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-19","payableDate":"2025-09-16","currency":"USD","dateTimestamp":1757995200000,"payDate":"2025-09-19"},{"date":"2025-06-16","symbol":"HDV","amount":0.91309,"announcedDate":"2025-06-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-16","defaultRemindTime":1750080600000,"name":"iShares High Dividend Equity Fun","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-20","payableDate":"2025-06-16","currency":"USD","dateTimestamp":1750046400000,"payDate":"2025-06-20"},{"date":"2025-03-18","symbol":"HDV","amount":0.795075,"announcedDate":"2025-03-17","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-18","defaultRemindTime":1742304600000,"name":"iShares High Dividend Equity Fun","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-21","payableDate":"2025-03-18","currency":"USD","dateTimestamp":1742270400000,"payDate":"2025-03-21"},{"date":"2024-12-17","symbol":"HDV","amount":1.12172,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares High Dividend Equity Fun","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HDV\",market:\"US\",,,undefined,":[{"executeDate":"2016-03-23","recordDate":"2016-03-28","paymentDate":"2016-03-30","value":0.676805,"currency":"USD"},{"executeDate":"2016-06-21","recordDate":"2016-06-23","paymentDate":"2016-06-27","value":0.679421,"currency":"USD"},{"executeDate":"2016-09-26","recordDate":"2016-09-28","paymentDate":"2016-09-30","value":0.687623,"currency":"USD"},{"executeDate":"2016-12-21","recordDate":"2016-12-23","paymentDate":"2016-12-28","value":0.655685,"currency":"USD"},{"executeDate":"2017-03-24","recordDate":"2017-03-28","paymentDate":"2017-03-30","value":0.7228843,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HDV\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HDV\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2606209062","title":"Libevitug Approved in China as First-in-Class Hepatitis D Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2606209062","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606209062?lang=en_us&edition=fundamental","pubTime":"2026-01-27 16:15","pubTimestamp":1769501700,"startTime":"0","endTime":"0","summary":"BEIJING, Jan. 27, 2026 /PRNewswire/ -- Huahui Health announced that China's National Medical Products Administration  has granted conditional approval to its Libevitug injection for chronic hepatitis D virus  infection in adults with or without compensated cirrhosis. Libevitug is a human monoclonal antibody targeting the PreS1 domain of hepatitis B virus  and HDV envelope proteins, blocking viral entry into hepatocytes. As a groundbreaking advance in viral hepatitis care, it is China's first approved HDV therapy and a first-in-class antibody for viral hepatitis, addressing a critical clinical gap.According to the World Health Organization , HDV affects nearly 5%  of people with chronic HBV infection. HDV–HBV co-infection is considered the most severe form of chronic viral hepatitis due to more rapid progression towards hepatocellular carcinoma and liver-related death.","market":"sg","thumbnail":"https://mma.prnewswire.com/media/2870372/image1.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2870372/image1.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/libevitug-approved-in-china-as-first-in-class-hepatitis-d-treatment-302670977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALT","BK4588","BK4599","BK4139","LU1878469433.USD","BK4585","HDV"],"gpt_icon":0},{"id":"2603635736","title":"Vir Biotechnology: Strengthening Best-in-Class HDV Profile with Robust SOLSTICE Data, Strategic Partnerships, and Sufficient Cash Runway Supporting Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2603635736","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603635736?lang=en_us&edition=fundamental","pubTime":"2026-01-13 23:46","pubTimestamp":1768319170,"startTime":"0","endTime":"0","summary":"Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Vir Biotechnology. The associated price target remains the same wit...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/vir-biotechnology-strengthening-best-in-class-hdv-profile-with-robust-solstice-data-strategic-partnerships-and-sufficient-cash-runway-supporting-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/vir-biotechnology-strengthening-best-in-class-hdv-profile-with-robust-solstice-data-strategic-partnerships-and-sufficient-cash-runway-supporting-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HDV"],"gpt_icon":0},{"id":"2581388662","title":"Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®","url":"https://stock-news.laohu8.com/highlight/detail?id=2581388662","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581388662?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:00","pubTimestamp":1762520400,"startTime":"0","endTime":"0","summary":"– Phase 1b data demonstrating favorable safety and tolerability profile and potent reductions in viral nucleic acids highlighted in late-breaking poster presentation – SOUTH SAN FRANCISCO, Calif., Nov","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/07/3183614/16259/en/Assembly-Biosciences-Presents-Positive-Phase-1b-Data-for-Next-Generation-Capsid-Assembly-Modulator-ABI-4334-at-AASLD-The-Liver-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAM","ABI","ASMB","BK4585","HDV","BK4588","BK4139"],"gpt_icon":0},{"id":"2581589057","title":"Vir Biotechnology’s Strategic Advancements in HDV and Oncology Programs Justify Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2581589057","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581589057?lang=en_us&edition=fundamental","pubTime":"2025-11-06 17:05","pubTimestamp":1762419947,"startTime":"0","endTime":"0","summary":"Needham analyst Joseph Stringer has maintained their bullish stance on VIR stock, giving a Buy rating yesterday. Joseph Stringer has given his Buy ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/vir-biotechnologys-strategic-advancements-in-hdv-and-oncology-programs-justify-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/vir-biotechnologys-strategic-advancements-in-hdv-and-oncology-programs-justify-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HDV"],"gpt_icon":0},{"id":"1194327810","title":"RiboBio's HK IPO Journey: Balanced Pipeline and \"China's Alnylam\" Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1194327810","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194327810?lang=en_us&edition=fundamental","pubTime":"2025-10-31 09:16","pubTimestamp":1761873391,"startTime":"0","endTime":"0","summary":"From chronic medication to one-time or long-term interventions, small nucleic acid drugs are redefining treatment paradigms, highlighting the \"blue ocean\" potential of this market. With programmable...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","BK4585","BK4588","EMA","HDV"],"gpt_icon":0},{"id":"2577597889","title":"Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection","url":"https://stock-news.laohu8.com/highlight/detail?id=2577597889","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577597889?lang=en_us&edition=fundamental","pubTime":"2025-10-24 18:12","pubTimestamp":1761300720,"startTime":"0","endTime":"0","summary":"BEIJING and GOTHENBURG, Sweden, Oct. 24, 2025 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. andRibocure Pharmaceuticals AB ,today announcedthat the European Medicines Agency  has granted Orphan Drug Designation  to RBD1016 for the treatment of Hepatitis D Virus  infection.About Hepatitis D Virus HDV is the most severe form of viral hepatitis and occurs only in individuals co-infected with hepatitis B virus . HDV accelerates liver disease progression, significantly increasing the risk of cirrhosis, liver failure, and hepatocellular carcinoma. It is estimated that 12–20 million people globally are affected by HDV, with limited therapeutic options currently available.Despite its severity, HDV remains underdiagnosed and underserved. The development of targeted therapies like RBD1016 offers a promising path forward for patients and clinicians seeking more effective and durable treatment options.Suzhou Ribo Life Science Co. Ltd. is a pioneer in advancing RNAi technology and industrializ","market":"other","thumbnail":"https://mma.prnewswire.com/media/2804420/logo_Ribolia_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2804420/logo_Ribolia_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/ribo-granted-ema-orphan-drug-designation-for-sirna-therapeutic-rbd1016-for-hepatitis-delta-virus-hdv-infection-302593816.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","BK4183","HDV","ODD","EMA","BK4588","IE0009354923.USD","BK4585"],"gpt_icon":0},{"id":"2575291290","title":"Assembly Biosciences Announces Upcoming Investor Conference Participation","url":"https://stock-news.laohu8.com/highlight/detail?id=2575291290","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575291290?lang=en_us&edition=fundamental","pubTime":"2025-10-14 19:00","pubTimestamp":1760439600,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Oct.  14, 2025  (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/14/3166009/16259/en/Assembly-Biosciences-Announces-Upcoming-Investor-Conference-Participation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","HDV","BK4139","ASMB"],"gpt_icon":0},{"id":"2574017554","title":"Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2574017554","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574017554?lang=en_us&edition=fundamental","pubTime":"2025-10-10 20:00","pubTimestamp":1760097600,"startTime":"0","endTime":"0","summary":"– Late-breaking oral presentation highlights interim Phase 1b data reported earlier this year for two cohorts in participants with recurrent genital herpes – – Statistically significant reductions in ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/10/3164831/16259/en/Assembly-Biosciences-Presents-Interim-Phase-1b-Data-for-HSV-Helicase-Primase-Inhibitor-Candidate-ABI-5366-at-the-38th-Congress-of-the-International-Union-Against-Sexually-Transmitt.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASMB","BK4585","BK4588","BK4139","ABI","HDV"],"gpt_icon":0},{"id":"2567350145","title":"Vir Biotechnology: Strategic Dual-Franchise Growth and Promising Oncology and HDV Developments Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2567350145","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567350145?lang=en_us&edition=fundamental","pubTime":"2025-09-15 23:55","pubTimestamp":1757951727,"startTime":"0","endTime":"0","summary":"Vir Biotechnology, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from H.C. Wainwright reite...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/vir-biotechnology-strategic-dual-franchise-growth-and-promising-oncology-and-hdv-developments-support-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/vir-biotechnology-strategic-dual-franchise-growth-and-promising-oncology-and-hdv-developments-support-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HDV"],"gpt_icon":0},{"id":"2564531124","title":"Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2564531124","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564531124?lang=en_us&edition=fundamental","pubTime":"2025-09-04 04:05","pubTimestamp":1756929900,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Sept.  03, 2025  (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through bes","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/03/3144039/0/en/Aligos-Therapeutics-Announces-Six-Preclinical-Presentations-at-the-2025-International-HBV-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","ASO","BK4585","LENZ","HDV","BK4505","BK4007","BK4200","ALGS","BK4139","BK4561","ITM","BK4539"],"gpt_icon":0},{"id":"2557524972","title":"Assembly Biosciences Announces Pricing of $175 Million in Equity Financings","url":"https://stock-news.laohu8.com/highlight/detail?id=2557524972","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557524972?lang=en_us&edition=fundamental","pubTime":"2025-08-08 20:05","pubTimestamp":1754654700,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Aug.  08, 2025  (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (“Assembly Bio”) (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting seriou","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/08/3130118/16259/en/Assembly-Biosciences-Announces-Pricing-of-175-Million-in-Equity-Financings.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EQR","BK4585","BK4588","HDV","BK4139","ASMB","BK4215"],"gpt_icon":0},{"id":"2557521710","title":"Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes","url":"https://stock-news.laohu8.com/highlight/detail?id=2557521710","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557521710?lang=en_us&edition=fundamental","pubTime":"2025-08-08 20:00","pubTimestamp":1754654400,"startTime":"0","endTime":"0","summary":"– 94% reduction in HSV-2 shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed in cohort evaluating 350mg weekly oral dose compared to placebo over","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/08/3130113/16259/en/Assembly-Biosciences-Reports-Positive-Interim-Results-from-Phase-1b-Clinical-Study-of-Long-Acting-Helicase-Primase-Inhibitor-Candidate-ABI-5366-Showing-Reductions-in-Viral-Shedding.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","ASMB","BK4218","ABI","SD","BK4181","BK4588","BK4139","PK","BK4585","HDV"],"gpt_icon":0},{"id":"2557307216","title":"Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2557307216","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557307216?lang=en_us&edition=fundamental","pubTime":"2025-08-07 04:05","pubTimestamp":1754510700,"startTime":"0","endTime":"0","summary":"– On track for proof-of-concept Phase 1b data no later than this fall in participants with recurrent genital herpes for long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidates, AB","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/06/3128647/16259/en/Assembly-Biosciences-Reports-Second-Quarter-2025-Financial-Results-and-Recent-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASMB","BK4139","BK4181","BK4588","PK","BK4585","HDV","BK4218"],"gpt_icon":0},{"id":"2557077723","title":"Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus","url":"https://stock-news.laohu8.com/highlight/detail?id=2557077723","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557077723?lang=en_us&edition=fundamental","pubTime":"2025-08-07 04:05","pubTimestamp":1754510700,"startTime":"0","endTime":"0","summary":"– Data to date in single- and multiple-ascending dose cohorts of healthy participants demonstrate a four-day half-life for ABI-6250, supporting target daily oral dosing profile and dose-dependent elev","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/06/3128674/16259/en/Assembly-Biosciences-Reports-Interim-Phase-1a-Data-from-Clinical-Study-of-Oral-Entry-Inhibitor-Candidate-ABI-6250-for-Hepatitis-Delta-Virus.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABI","ASMB","LU1878469433.USD","HDV","BK4588","BK4599","BK4585","BK4139","BK4218","ALT","BK4181","PK"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":14,"code":"91000000","status":"200"}]}}